• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial
Conclusion In the CHAMPION PHOENIX trial, MVD and SVD patients had similar ischemic outcomes at 48hours and 30days. Cangrelor consistently reduced ischemic complications in both SVD and MVD patients without a significant increase in GUSTO severe bleeding. Clinical perspectives What's known? Cangrelor is a novel, intravenous, potent, and rapidly acting P2Y12 inhibitor that has been demonstrated to reduce the rate of ischemic events at 48hours in patients who received PCI compared with clopidogrel. What's new? In contrast to prior studies, we found that in this modern cohort, patients with SVD and MVD had a similar risk of i...
Source: American Heart Journal - April 18, 2017 Category: Cardiology Source Type: research

Primary percutaneous coronary intervention at centers with and without on-site surgical support: Insights from the blue cross blue shield of Michigan cardiovascular consortium (BMC2)
Conclusions Primary PCI performed at centers with and without cardiac surgery have comparable outcomes and complication rates, when performed with close monitoring of quality and outcomes.
Source: American Heart Journal - October 17, 2017 Category: Cardiology Source Type: research

International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and design
Conclusions ISCHEMIA will provide new scientific evidence regarding whether an invasive management strategy improves clinical outcomes when added to optimal medical therapy in patients with SIHD and moderate or severe ischemia.
Source: American Heart Journal - May 26, 2018 Category: Cardiology Source Type: research

Outcomes of left Main revascularization in patients with acute coronary syndromes and stable ischemic heart disease: Analysis from the EXCEL trial
ConclusionsThe acuity of presentation did not predict outcomes in patients with LMCAD undergoing revascularization, nor did it discriminate patients who derive greater event-free survival from PCI versus CABG.
Source: American Heart Journal - May 4, 2019 Category: Cardiology Source Type: research

Long-Term (10-Year) Outcomes of Stenting or Bypass Surgery for Acute Coronary Syndromes and Stable Ischemic Heart Disease With Unprotected Left Main Coronary Artery Disease
ConclusionsIn patients with LMCA disease, we have identified no significant interaction between the acuity of clinical indication and the relative treatment effect of PCI versus CABG on 10-year clinical outcomes.
Source: American Heart Journal - August 22, 2019 Category: Cardiology Source Type: research

Association of Postoperative Complications and Outcomes Following Coronary Artery Bypass Grafting
ConclusionsPostoperative complications are associated with an increased risk of both early and late mortality and all-cause rehospitalization, particularly during the “value” window within 90 days of CABG. These findings underscore the need to develop avoidance strategies as well as cost-adjustment methods for each of these complications.
Source: American Heart Journal - February 9, 2020 Category: Cardiology Source Type: research

Pages: 1  2  3